Status:

UNKNOWN

Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma

Lead Sponsor:

Armando Santoro, MD

Conditions:

Hodgkin's Lymphoma

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

study to assess maximum tolerated dose (MTD), safety, tolerability and activity of IGEV (Ifosfamide, Gemcitabine,Vinorelbine, Prednisolone) + Panobinostat new combination in order to determine the rec...

Detailed Description

Patients will received 4 p-IGEV courses repeated every 3 weeks in the absence of unacceptable toxicity, whenever an objective response is observed at disease evaluation performed after II cycle. Elig...

Eligibility Criteria

Inclusion

  • Diagnosis of relapsed or refractory classical HL
  • Measurable disease
  • One or two prior systemic lines of treatment
  • PS(ECOG) 0-2
  • Absence of bone marrow infiltration
  • Adequate laboratory values for bone marrow, liver and renal functionality

Exclusion

  • prior or concurrent treatment with a DAC inhibitor including panobinostat
  • valproic acid therapy for any medical condition during the study or within 5 days prior to the first panobinostat treatment
  • previous autologous hematopoietic stem cell transplant
  • other concurrent therapy intended to treat the primary cancer including chemotherapy, investigational or biologic agents or other antitumor agents
  • impaired cardiac function or unstable AF
  • known history of HIV seropositivity, chronic hepatitis, or other active viral infections
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, obstruction, or stomach and/or small bowel resection)
  • pregnant or breast feeding women

Key Trial Info

Start Date :

July 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2015

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT01884428

Start Date

July 1 2011

End Date

December 1 2015

Last Update

January 29 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Istituto Clinico Humanitas

Rozzano, MI, Italy, 20089